November 08, 2024

Tanning Bed Access, Usage May Be Driving Higher Rates of Melanoma in New England

Investigators have uncovered a potential link between the availability and use of tanning beds and the rising rates of melanoma in a specific region.

The ASCO Post

November 04, 2024

My Melanoma Could Have Been Prevented

“I have many of the risk factors for melanoma. I’m fair-skinned, blue-eyed, and have a family history of melanoma, as well as other skin cancers, so I’ve always been diligent about practicing sun safe...

The ASCO Post

November 04, 2024

Immunotherapy Combination May Demonstrate Benefit in Patients With Cutaneous Melanoma

Presurgical treatment with a combination of novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve tumor control in patients with stage III cutaneous melanoma.

The ASCO Post

October 24, 2024

Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care

Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) ...

The ASCO Post

January 05, 2024

Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer

Researchers investigated the potential of a rare subset of T cells to predict which patients with advanced skin cancer may be responsive to immunotherapy.

The ASCO Post

June 23, 2023

Expert Point of View: Zeynep Eroglu, MD

Dr. Zeynep Eroglu discusses the remarkable response of desmoplastic melanoma to pembrolizumab and proposes potential approaches for therapy and surgery.

The ASCO Post

August 21, 2023

Ipilimumab Plus Nivolumab May Improve Outcomes in Patients With Refractory Metastatic Melanoma, Study Suggests

Researchers have discovered that ipilimumab in combination with nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent s...

The ASCO Post

April 17, 2023

Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma

Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by...

The ASCO Post

September 19, 2023

Previously Untreated Advanced Melanoma: Addition of Bempegaldesleukin to Nivolumab

In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues investigated the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodru...

The ASCO Post